15May 2024
MediciNova Secures Patent for MN-166 in Chlorine-Induced ARDS Treatment

MediciNova Secures Patent for MN-166 in Chlorine-Induced ARDS Treatment

MediciNova, Inc. has attained a U.S. Patent and Trademark Office for a patent application concerning MN-166 (ibudilast) in treating chlorine-induced acute respiratory distress syndrome (ARDS). The patent claims encompass MN-166's application as a standalone therapy or in combination with other drugs for chlorine-induced ARDS treatment. Recent studies have showcased MN-166's notable efficacy, significantly enhancing pulmonary function and survival rates in chlorine-induced lung damage models. MN-166 operates by inhibiting phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). Besides ARDS, MN-166 is undergoing late-stage clinical development for neurodegenerative ailments like ALS, MS, and DCM, alongside exploration for conditions such as glioblastoma, Long COVID, CIPN, substance use disorder, and in ARDS-risk patients

  • #family health

Like

Save

Share